Dr Roger Aston

Dr Aston has more than 20 years experience in the pharmaceutical and biotechnology industries and has been closely involved in organisational restructuring of companies and in improving effectiveness and productivity.

His previous positions include director of Cambridge Antibody Technology Limited (UK), Chairman of Cambridge Drug Discovery Limited (UK) (now BioFocus plc), founder and CEO of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group as well as CEO of Peptech Limited, founder and CEO of UK-based pSiMedica Limited, CEO of pSiOncology, Dr Aston was Executive Chairman of Clinuvel Limited until late 2007 (ASX:CUV) and consults for BIO-IB Inc.

Aspects of his experience include FDA registration and CTX and CTN submissions to European and Australian authorities, clinical trials, global licensing agreements, fundraising through private placements, preparation of prospects for a public offering, and a network of contacts within the pharmaceutical, banking and stock broking sectors.